Topic
Clinical pharmacology
About: Clinical pharmacology is a research topic. Over the lifetime, 3750 publications have been published within this topic receiving 74149 citations. The topic is also known as: Pharmacology, Clinical.
Papers published on a yearly basis
Papers
More filters
•
01 Jan 1982
TL;DR: Basic and clinical pharmacology , Basic and clinical Pharmacology , کتابخانه دیجیتال جندی شاپور اهواز
Abstract: Basic and clinical pharmacology , Basic and clinical pharmacology , کتابخانه دیجیتال جندی شاپور اهواز
2,420 citations
••
TL;DR: Ketamine—Its Pharmacology and Therapeutic Uses Paul white;Walter Way;anthony Trevor; Anesthesiology
Abstract: Ketamine—Its Pharmacology and Therapeutic Uses Paul white;Walter Way;anthony Trevor; Anesthesiology
1,415 citations
••
TL;DR: This book succeeds Review of Medical Pharmacology, by Meyers, Jawetz, and Goldfien, and deals with relevant information regarding the clinical use of drugs on the various battlefields.
Abstract: This book succeeds Review of Medical Pharmacology , by Meyers, Jawetz, and Goldfien. Edited by B. G. Katzung, some of the important areas covered include drug receptors and pharmacodynamics, pharmacokinetics of absorption and biotransformation of drugs, autonomic pharmacology of cholinergic and adrenergic receptor stimulants and antagonists, antihypertensive agents, cardiac glycosides and other agents used in the treatment of congestive heart failure, therapeutic drugs for cardiac arrhythmias, diuretics, pharmacology of the CNS drugs such as anticonvulsants and anesthetics, antidepressants, narcotic analgesics, nonsteroidal anti-inflammatory agents, endocrine pharmacology, antimicrobial and antimycobacterial drugs, antiprotozoal and antihelmintic drugs, cancer chemotherapy, and drugs and the immune system. Written by several prominent researchers and scientists, each chapter begins with a section on the basic pharmacology, chemistry, pharmacokinetics, and pharmacodynamics of the agents under discussion. This is followed by a section on clinical pharmacology, which deals with relevant information regarding the clinical use of drugs on the various
859 citations
••
TL;DR: 5-Fluorouracil, first introduced as a rationally synthesised anticancer agent 30 years ago, continues to be widely used in the management of several common malignancies including cancer of the colon, breast and skin.
Abstract: 5-Fluorouracil, first introduced as a rationally synthesised anticancer agent 30 years ago, continues to be widely used in the management of several common malignancies including cancer of the colon, breast and skin. This drug, an analogue of the naturally occurring pyrimidine uracil, is metabolised via the same metabolic pathways as uracil. Although several potential sites of antitumour activity have been identified, the precise mechanism of action and the extent to which each of these sites contributes to tumour or host cell toxicity remains unclear. Several assay methods are available to quantify 5-fluorouracil in serum, plasma and other biological fluids. Unfortunately, there is no evidence that plasma drug concentrations can predict antitumour effect or host cell toxicity. The recent development of clinically useful pharmacodynamic assays provides an attractive alternative to plasma drug concentrations, since these assays allow the detection of active metabolites of 5-fluorouracil in biopsied tumour or normal tissue. 5-Fluorouracil is poorly absorbed after oral administration, with erratic bioavailability. The parenteral preparation is the major dosage form, used intravenously (bolus or continuous infusion). Recently, studies have demonstrated the pharmacokinetic rationale and clinical feasibility of hepatic arterial infusion and intraperitoneal administration of 5-fluorouracil. In addition, 5-fluorouracil continues to be used in topical preparations for the treatment of malignant skin cancers. Following parenteral administration of 5-fluorouracil, there is rapid distribution of the drug and rapid elimination with an apparent terminal half-life of approximately 8 to 20 minutes. The rapid elimination is primarily due to swift catabolism of 5-fluorouracil in the liver. As with all drugs, caution should be used in administering 5-fluorouracil in various pathophysiological states. In general, however, there are no set recommendations for dose adjustment in the presence of renal or hepatic dysfunction. Drug interactions continue to be described with other antineoplastic drugs, as well as with other classes of agents.
847 citations
•
01 Jan 2018
TL;DR: Basic & clinical pharmacology, Basic & clinical Pharmacology , کتابخانه دیجیتال جندی شاپور اهواز
Abstract: Basic & clinical pharmacology , Basic & clinical pharmacology , کتابخانه دیجیتال جندی شاپور اهواز
829 citations